Carfizome 60mg Injection (Carfilzomib)

Carfizome 60mg Injection is a prescription medicine containing Carfilzomib. It is supplied in a 60mg injection presentation and belongs to the proteasome inhibitor class. It should be used only under the supervision of a clinician experienced in the relevant disease area.
Relapsed or refractory multiple myeloma: carfilzomib Injection is used in adults who have received prior therapy, either as a single agent or in approved combinations. Current labeling includes combinations with dexamethasone, lenalidomide/dexamethasone, daratumumab/dexamethasone, daratumumab-hyaluronidase/dexamethasone, or isatuximab/dexamethasone in defined prior-treatment settings.
Carfilzomib 60mg Injection irreversibly binds to active sites of the 20S proteasome within the 26S proteasome, inhibiting proteolytic activity. Proteasome inhibition disrupts protein homeostasis and can promote apoptosis in plasma cells, which have a high burden of protein production. The 60mg strength describes the commercial presentation; it does not automatically represent the complete prescribed dose. Dose and duration depend on diagnosis, treatment protocol, organ function, concomitant medicines and treatment tolerance.

Carfizome 60mg Injection may be prescribed in the following established clinical settings. The exact treatment line, combination regimen and duration depend on the diagnosis, current labeling and specialist assessment.
Relapsed or refractory multiple myeloma: Carfilzomib 60mg is used in adults who have received prior therapy, either as a single agent or in approved combinations.
Current labeling includes combinations with dexamethasone, lenalidomide/dexamethasone, daratumumab/dexamethasone, daratumumab-hyaluronidase/dexamethasone, or isatuximab/dexamethasone in defined prior-treatment settings.

Carfilzomib 60mg Injection irreversibly binds to active sites of the 20S proteasome within the 26S proteasome, inhibiting proteolytic activity. Proteasome inhibition disrupts protein homeostasis and can promote apoptosis in plasma cells, which have a high burden of protein production.

• Clinical evidence in this section relates to the Carfilzomib 60mg molecule and relevant treatment regimens; it should not be interpreted as evidence that every pivotal trial specifically studied the Carfizome 60mg commercial presentation.
  
• Randomized studies support multiple carfilzomib Injection-containing regimens in relapsed/refractory multiple myeloma.
  
• The clinical outcome depends on the partner drugs, prior treatment, cytogenetic risk, disease burden and patient fitness.
  
• Evidence applies to carfilzomib Injection regimens, not specifically to the Carfizome 60mg commercial vial.
  
  

The side effects of Carfilzomib 60mg Injection vary by indication, dose, treatment duration, concomitant medicines and individual patient factors. Common or clinically relevant effects include:

• Anemia
  
• Thrombocytopenia
  
• Fatigue
  
• Diarrhea
  
• Nausea
  
• Shortness of breath
  
• Fever
  
• Hypertension
  
• Respiratory infections

Serious or persistent symptoms should be assessed promptly. The treating team should provide medicine-specific instructions on which symptoms require urgent medical attention.

These are molecule-level examples from regulatory labeling or established product information and are not instructions for self-dosing. The treating specialist determines the actual dose, schedule, dose modifications and supportive medicines.

Carfizome Injection is given according to a scheduled treatment plan. If an appointment or dose is missed or delayed, contact the treating team promptly. Do not attempt to compensate for a missed Carfilzomib 60mg dose or alter the treatment cycle without medical advice.

Monitoring is individualized according to the disease and treatment regimen. It may include:

• CBC and platelets
  
• Renal function
  
• Blood pressure
  
• Cardiac symptoms/function when indicated
  
• Liver enzymes
  
• Tumour lysis parameters
  
• Infusion reactions
  
• Pulmonary symptoms
  
• Myeloma response markers
  

1. DailyMed. KYPROLIS (carfilzomib) prescribing information https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ea66eb30-e665-4693-99a1-a9d3b4bbe2d6​
2. Current multiple-myeloma treatment guidelines https://themmrf.org/diagnosis-and-treatment/treatment-options/​
3. Current India-specific Carfizome package insert before publication https://5.imimg.com/data5/SELLER/Doc/2024/3/398991605/ZO/AM/AO/10833908/carfilzomib-injection-60mg.pdf​
4. Brand-specific Carfizome prescribing information / package insert should remain the primary source for manufacturer, exact dosage form, storage, pack configuration and India-specific approved labeling before publication.